Anavex Life Sciences' Alzheimer's Candidate Mechanism Of Action Explained In Medical Journal

  • Anavex Life Sciences Corp AVXL has reported that ANAVEX 2-73 (blarcamesine) and ANAVEX3-71 (AF710B) are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets.
  • Scientific Paper Highlights:
    • Sigma-1 receptor (SIGMAR1)'s expression increases with age. However, in Alzheimer's disease (AD), it decreases and coincides with an age-related decrease in autophagy.
    • The SIGMAR1 may compensate for the loss of receptors and autophagic machinery during healthy aging.
    • ANAVEX-compounds activate SIGMAR1 and induce autophagy, a phenomenon that clears damaged cellular organelles and misfolded proteins.
    • Activation of the SIGMAR1 can induce cytoprotective autophagic pathways.
    • ANAVEX-compounds have also exhibited to block toxic Aβ, tau, and neuroinflammation.
  • Price Action: AVXL shares are up 20.7% at $18.71 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralAlzheimer's diseaseBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!